0000000000618657

AUTHOR

Touchard D

showing 2 related works from this author

Effect of cytomegalovirus-induced immune response, self antigen-induced immune response, and microbial translocation on chronic immune activation in …

2013

International audience; We evaluated the impact of cytomegalovirus (CMV)-induced immune responses, autoimmune-induced immune responses, and microbial translocation on immune activation in 191 human immunodeficiency virus type 1-infected patients from the ANRS CO3 Aquitaine Cohort. All enrolled subjects had achieved long-term virological suppression during receipt of combination antiretroviral therapy (cART). HLA-DR(+)/CD38(+) expression was 16.8% among CD8(+) T cells. Independent of age, CD4(+) T-cell count, 16S ribosomal DNA load, and regulatory T-cell count, positive results of Quantiferon CMV analysis (P = .02), positive results of CMV-pp65 enzyme-linked immunosorbent spot analysis (P = …

MaleCytomegalovirusAutoimmunityHIV InfectionsCD8-Positive T-LymphocytesCD38Lymphocyte Activationmedicine.disease_causeAutoimmunityCohort Studies0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyAntiretroviral Therapy Highly ActiveImmunology and Allergy030212 general & internal medicineMESH: Cytomegalovirus Infections/immunologyMESH: HLA-DR Antigens/metabolismMESH: Cohort Studies0303 health sciencesMESH: HIV Infections/drug therapyvirus diseasesViral Load3. Good healthInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyMESH: CD8-Positive T-Lymphocytes/immunologyCytomegalovirus Infections[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleFranceMESH: Cytomegalovirus/immunologyMESH: Viral Load[SDV.IMM] Life Sciences [q-bio]/ImmunologyCongenital cytomegalovirus infectionHuman leukocyte antigenBiologyQuantiFERONViral Matrix Proteins03 medical and health sciencesImmune systemMESH: Cross-Sectional StudiesAntigenMESH: AutoimmunitymedicineHumansMESH: Phosphoproteins/immunology[SDV.MP] Life Sciences [q-bio]/Microbiology and ParasitologyMESH: Viral Matrix Proteins/immunology030304 developmental biologyMESH: HumansMESH: HIV-1/geneticsMESH: HIV-1/physiologyMESH: HIV Infections/immunologyHLA-DR AntigensPhosphoproteinsmedicine.diseaseVirologyMESH: MaleMESH: Lymphocyte Activation/immunologyMESH: FranceCross-Sectional Studies[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieImmunologyHIV-1[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieMESH: HIV-1/drug effectsMESH: FemaleCD8
researchProduct

Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are creat…

2009

Contains fulltext : 80963.pdf (Publisher’s version ) (Open Access) BACKGROUND: The extent to which mortality differs following individual acquired immunodeficiency syndrome (AIDS)-defining events (ADEs) has not been assessed among patients initiating combination antiretroviral therapy. METHODS: We analyzed data from 31,620 patients with no prior ADEs who started combination antiretroviral therapy. Cox proportional hazards models were used to estimate mortality hazard ratios for each ADE that occurred in >50 patients, after stratification by cohort and adjustment for sex, HIV transmission group, number of antiretroviral drugs initiated, regimen, age, date of starting combination antiretrovir…

MaleInfectious diseases and international health [NCEBP 13]Lymphoma030312 virologyEsophageal candidiasisCohort Studies0302 clinical medicineInterquartile range030212 general & internal medicineAIDS-RelatedLymphoma AIDS-Related0303 health sciencesMortality rateProgressive multifocal leukoencephalopathyHazard ratioPrognosis3. Good healthPathogenesis and modulation of inflammation [N4i 1]Infectious DiseasesCombinationDrug Therapy CombinationFemaleInfection and autoimmunity [NCMLS 1]HumanMicrobiology (medical)Adultmedicine.medical_specialtyPrognosiAnti-HIV Agentsantiretroviral therapyInfectious DiseaseArticleAIDS-Related Opportunistic Infection03 medical and health sciencesAcquired immunodeficiency syndrome (AIDS)Drug TherapyInternal medicinemedicineHumansAIDS-defining eventProportional Hazards ModelsAIDS-Related Opportunistic Infections/diagnosis/ mortality; Acquired Immunodeficiency Syndrome/complications/diagnosis/drug; therapy/ mortality; Adult; Anti-HIV Agents/ therapeutic use; Cohort Studies; Drug Therapy; Combination; Female; Humans; Lymphoma; AIDS-Related/diagnosis/mortality; Male; Prognosis; Proportional Hazards ModelsAcquired Immunodeficiency SyndromeAIDS-Related Opportunistic Infectionsbusiness.industryProportional hazards modelPoverty-related infectious diseases [N4i 3]Anti-HIV Agentmedicine.diseasemortalityConfidence intervalImmunologyProportional Hazards ModelCohort Studiebusiness
researchProduct